20.500.12556/RUL-165843 Impact of regulatory risk communication on thrombosis with thrombocytopenia syndrome for COVID-19 adenovirus vector vaccines on European Healthcare Professionals Purpose: The European Medicines Agency (EMA) issued regulatory actions and communications in 2021 on thrombosis withthrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines Vaxzevria or Jcovden. This study aimed to eval-uate the impact of these actions on awareness, knowledge and implementation in practises of healthcare professionals (HCP).Methods: Web-based cross-sectional surveys were conducted on HCPs engaged in the vaccination, monitoring or counsellingabout the vaccines. We measured awareness and knowledge of the risk of TTS and their implementation of recommendationsin practise. Descriptive and qualitative analyses were conducted. This study took place in Greece, Latvia, Netherlands, Portugaland Slovenia. Results: We surveyed 1659 HCPs. From these, 914 were included in the analysis. Most were aware about the reports of TTSassociated with COVID-19 adenovirus vector vaccines, with countries reporting percentages between 85% and 97%. Mainstreammedia, health authorities and peers were the main sources of TTS risk information. Most HCPs were able to identify key symptoms from TTS but were less familiar with minor symptoms. Guidelines from health authorities on COVID-19 vaccinationimpacted on professional practise of 55%–77% of HCPs. The reported use of product information across countries was moderate,with some variations. Conclusions: Awareness about and knowledge of TTS risk from COVID-19 adenoviral vector vaccines were high among HCPs.HCPs reported a clear preference for national guidelines as source of risk information and the implementation of product infor-mation remained moderate across countries. COVID-19 vaccines healthcare professionals regulatory actions risk communication SARS- CoV-2 adenovirus vector vaccines thrombosis with thrombocytopenia syndrome regulativni ukrepi zdravstveni delavci tromboza s trombocitopeničnim sindromom tromboza cepiva SARS-CoV-2 COVID-19 true false true Angleški jezik Slovenski jezik Članek v reviji 2024-12-12 09:21:12 2024-12-12 09:21:13 2024-12-13 03:57:45 0000-00-00 00:00:00 2024 0 0 14 str. iss. 12, [article e70057] Vol. 33 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 615.371:616-005.6 1053-8569 10.1002/pds.70057 216692483 Pharmacoepidemiology_and_Drug_-_2024_-_van_Vliet_-_Impact_of_Regulatory_Risk_Communication_on_Thrombosis_With.pdf Pharmacoepidemiology_and_Drug_-_2024_-_van_Vliet_-_Impact_of_Regulatory_Risk_Communication_on_Thrombosis_With.pdf 1 752E2F82E042EEABCC6CCDD8273CF56D e700e9e8e7949e996b220157a285eed1e9c1c87e1d76ce6624b73c20e355a264 f315629f-b861-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=197095 https://onlinelibrary.wiley.com/doi/10.1002/pds.70057 1 8cf504e3-b861-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=197094 Fakulteta za farmacijo 0 0 0